1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Market Spotlight: Huntington’s Disease, Pharma Intelligence

Market Spotlight: Huntington’s Disease, Pharma Intelligence

  • October 2019
  • 35 pages
  • ID: 5780015
  • Format: PDF
  • By Pharma Intelligence

Summary

Table of Contents

Huntington’s disease (HD) is a rare disorder of the central nervous system (CNS) which causes the degeneration of nerve cells. It is an autosomal dominant disease characterized by involuntary choreatic movements, psychiatric and behavioral disturbances, and dementia. The mean age of symptom onset is 30–50 years. HD is caused by the presence of >40 cytosine-adenine-guanine (CAG) repeats within the Huntingtin gene. The length of the CAG repeats is inversely associated with the age of disease onset – the longer the repeat, the earlier the onset. In the case of juvenile HD (JHD), the length of the repeat is >55 and the disease’s symptoms are seen in patients aged <20 years. Learning disabilities and behavioral disturbances are the first symptoms in patients with JHD.

Key Takeaways
The analyst estimates that in 2017, there were 159,410 prevalent cases of Huntington’s disease (HD) in adults aged 30 years and older worldwide, and forecasts that number to increase to 184,950 prevalent cases by 2026.
Northern America is estimated to have the highest disease prevalence (0.0073%), while Asia has the lowest prevalence (0.0004%).
Teva’s Austedo and Bausch Health’s Xenazine, which target vesicular monamine transporters, are the only marketed drugs for HD. These drugs are administered via the oral route.
The majority of industry-sponsored drugs in active clinical development for HD are in Phase II, with two drugs in Phase III. Therapies in active clinical development for HD focus on targets such as lysosomal cysteine transporter, huntingtin, p38 MAP kinase, SIRT1, vasopressin receptors, semaphorin 4D/CD100, aryl hydrocarbon receptor, NMDA glutamate receptor, PPAR delta, and PPAR gamma. The majority of the pipeline drugs are administered via the oral route, with the remainder being intrathecal and intravenous formulations.
High-impact upcoming events for drugs in the HD space comprise topline Phase Ib/IIa trial results for WVE-120101 and WVE120102, and topline Phase II trial results for Pepinemab and HTT-ASO.
The overall likelihood of approval of a Phase I neurodegenerative asset is 7.3%, and the average probability a drug advances from Phase III is 47.8%. Drugs, on average, take 11.1 years from Phase I to approval, compared to 9.8 years in the overall neurology space.
There have been nine licensing and asset acquisition deals involving HD drugs during 2014–19. The $1,050m exclusive strategic collaboration and option agreement signed in 2018 between AbbVie and Voyager Therapeutics for the development and commercialization of vectorized antibodies directed against tau for the treatment of Alzheimer’s disease and other neurodegenerative diseases was the largest deal.
The distribution of clinical trials across Phase I–IV indicates that the majority of trials for HD have been in the early and midphases of development, with 77% of trials in Phase I–II, and only 23% in Phase III–IV.
The US has a substantial lead in the number of HD clinical trials globally, while the UK leads the major EU markets. Clinical trial activity in the HD space is dominated by completed trials. Pfizer and Teva have the highest number of completed clinical trials for HD, with 14 trials each.
Pfizer and Teva lead industry sponsors with the highest number of clinical trials for HD.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Acinetobacter Infections - Pipeline Review, H2 2019

Acinetobacter Infections - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Acinetobacter Infections - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Acinetobacter Infections - Pipeline Review, H2 2019, provides an overview of the ...

Pertussis (Whooping Cough) - Pipeline Review, H2 2019

Pertussis (Whooping Cough) - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Pertussis (Whooping Cough) - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Pertussis (Whooping Cough) - Pipeline Review, H2 2019, provides an overview ...

Rotavirus Infections - Pipeline Review, H2 2019

Rotavirus Infections - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Rotavirus Infections - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Rotavirus Infections - Pipeline Review, H2 2019, provides an overview of the Rotavirus ...


ref:plp2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on